Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer

August 1st 2025

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer

August 1st 2025

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Coordinated Care in Breast Oncology: Systemic Therapy Trials and Personalized Approaches

August 1st 2025

Experts explore how advances in systemic therapy are helping personalize and de-escalate breast cancer treatment.

Coordinated Care in Breast Oncology: Clinical Trials and De-escalation of Treatment

July 31st 2025

Experts discuss how coordinated clinical trial participation enables safer treatment de-escalation and advances breast cancer care through research efforts.

Coordinated Care in Breast Oncology: Tumor Board & Treatment Alignment

July 31st 2025

Experts discuss how coordinated tumor board reviews enhance continuity of care, treatment personalization, and patient confidence after breast cancer surgery.

Coordinated Care in Breast Oncology: Importance of Plastic Surgery & Genetic Counseling

July 30th 2025

Experts discuss how involving plastic surgeons and genetic counselors early in breast cancer care helps guide personalized surgical decisions.

FDA Approval of Dato‑DXd Expands Options for HR+, HER2‑Negative Metastatic Breast Cancer

July 30th 2025

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Building Treatment Algorithms Around Biomarker-Driven Therapies

July 30th 2025

Panelists discuss how treatment algorithms should differentiate between primary and secondary endocrine resistance, disease burden, and mutation status while looking forward to future combinations with oral selective estrogen receptor degraders (SERDs) and next-generation PIK3CA inhibitors with improved toxicity profiles to enable more effective precision medicine approaches.

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

July 30th 2025

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Gedatolisib-Based Regimens Prolong PFS in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

July 29th 2025

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

Coordinated Care in Breast Oncology: Role of Radiation Oncology

July 29th 2025

Experts discuss the importance of early multidisciplinary collaboration in breast cancer care, particularly involving radiation oncology at diagnosis.

Coordinated Care in Breast Oncology: Benefits of the Multidisciplinary Clinic

July 28th 2025

Experts discuss how a multidisciplinary clinic streamlines care and improves treatment planning for patients with newly diagnosed breast cancer.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Dr McCann on the Standard of Care for Managing ER+/HER2– Advanced Breast Cancer

July 23rd 2025

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer

July 23rd 2025

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Beyond Single Biomarkers: How Emerging Data Might Transform Biomarker Testing

July 23rd 2025

Panelists discuss how the SERENA-6 trial’s approach of serial liquid biopsy monitoring for ESR1 mutations raises important questions about the optimal timing and clinical benefit of molecularly guided therapy switches, with both experts preferring to see overall survival data before changing practice patterns.

Evolving Biomarker Testing Strategies for Earlier Detection in Metastatic Breast Cancer

July 23rd 2025

Panelists discuss how biomarker testing strategies have evolved from second-line to first-line metastatic disease, driven by the availability of targeted agents for PIK3CA and ESR1 mutations, with both tissue and liquid biopsy approaches being used to ensure timely results for treatment decision-making.

KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer

July 21st 2025

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Dr Rugo on the Safety Profile of Alpelisib in PI3K-Mutant HR+/HER2– Advanced Breast Cancer

July 18th 2025

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.